Basimglurant

Basimglurant
Systematic (IUPAC) name
2-chloro-4-{[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-yl]ethynyl}pyridine
Identifiers
CAS Number 802906-73-6
ATC code none
PubChem CID 11438771
ChemSpider 9613635
Chemical data
Formula C18H13ClFN3
Molar mass 325.767 g/mol

Basimglurant (INN) (code names RG-7090, RO4917523) is a negative allosteric modulator of the mGlu5 receptor which is under development by Roche for the treatment of treatment-resistant depression (as an adjunct) and fragile X syndrome.[1][2] As of August 2014, it is in phase II clinical trials for both of these indications.[1][2]

See also

References

  1. 1 2 "Roche - Pipeline". 2014. Retrieved 2014-08-01.
  2. 1 2 "Roche Group Development Pipeline" (PDF). 2014. Retrieved 2014-08-01.



This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.